curacleltd Valuation

Is A365270 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A365270 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A365270's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A365270's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A365270?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A365270. This is calculated by dividing A365270's market cap by their current preferred multiple.
What is A365270's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩87.96b

A365270 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.3x
Enterprise Value/EBITDA	-5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A365270's PS Ratio compare to its peers?

The above table shows the PS ratio for A365270 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.8x
A153710 Optipharm.CO.LTD	4x	n/a	₩74.2b
A263050 Eutilex.Co.Ltd	27.2x	n/a	₩82.4b
A049960 Cell Biotech	1.8x	n/a	₩95.0b
A950200 Psomagen	2.4x	n/a	₩81.0b
A365270 curacleltd	21.8x	n/a	₩88.0b

Price-To-Sales vs Peers: A365270 is expensive based on its Price-To-Sales Ratio (21.8x) compared to the peer average (8.8x).

Price to Earnings Ratio vs Industry

How does A365270's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	64.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	64.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: A365270 is expensive based on its Price-To-Sales Ratio (21.8x) compared to the KR Biotechs industry average (10.2x).

Price to Sales Ratio vs Fair Ratio

What is A365270's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A365270 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	21.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A365270's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.